17th EAHP meeting Istanbul, Turkey from 17 to 22 October 2014.
18 October 2014Saturday
Bone Marrow Symposium and Workshop Topic Saturday “Small B-cell lymphoid neoplasms in bone marrow: diagnostic advances”
The Bone Marrow Symposium and Workshop will be focused on small B-cell lymphoid neoplasms, particularly those predominantly studied and diagnosed in the bone marrow and peripheral blood. Particular relevance will be given to the use of newer technologies which by more precisely defining these entities will provide effective guidance in therapeutic decisions.
8:30-40: Welcome Address
Attilio Orazi & Isinsu Kuzu
BONE MARROW SYMPOSIUM
Chairs: Carlos Bueso-Ramos & Hans Kreipe
i. 8:40-9:10: Richard Rosenquist: Understanding the biology CLL in the light of newer technologies
ii. 9:15-9:45: Brunangelo Falini: Defining the genetic boundaries of other (non-CLL) small B cell lymphoid neoplasms typically encountered in bone marrow
iii. 9:50-10:15: Armando López-Guillermo: Targeted therapy strategies for both CLL and other small B cell neoplasms.
10:20-10:40: Coffee Break
Topic Lecture and Platform Presentations
Chairs: Hans-Michael Kvasnicka & Bogna Wroblewska
10:40-11:10: Elena Sabattini: Morphology and immunohistologic assessment of bone marrows involved by small B cell lymphoid neoplasms
11:15-12:15: Platforms Session (3-4 platform presentations from abstracts)
13:30-14:30: Chairs: Umberto Gianelli & Roos Leguit
BONE MARROW WORKSHOP:
Chairs: J van der Walt & M Safali- Diagnostic difficulties in CLL. Preference will be given to less common genetically defined subsets and/or morphologic variants, e.g., cases with plasmacytic differentiation, cases in early progression confirmed by genetic changes, cases clinically considered as monoclonal B cell lymphocytosis, their marrow and genetic correlates versus overt CLL.
15:30-16:00: Coffee Break and poster Viewing
Chairs: A Orazi & M Kremer - Bone marrow manifestations of LPL, MZL, SRPL, HCL-v, and HCL. Preference should be given to cases with adequate clinical and genetic information. In particular, we will be interested in cases in which the genetic results provide help in better defining provisional WHO entities such as SRPL and HCL-v, helping their differential diagnosis. Cases providing information in relation to the differential diagnosis of MZL in the bone marrow versus LPL would also be especially welcomed. Cases highlighting possible targets for targeted therapy would have precedence.
Chairs: A Porwit & F Fend - Small B-cell lymphomas in bone marrow: multiclonality and composite lymphomas. Examples include cases with coexisting two small B-cell lymphomas in the bone marrow and cases of B-cell lymphomas with discordant marrow versus nodal/extranodal findings.
Notes for the workshop (1-3):
Only cases with adequate immunophenotypic/molecular data will be considered for presentation and/or summary by the panel members. Respect of deadline for submission, adequate powerpoint presentation on CD, complete 10 unstained slides set are a must. Exclusions: alongside the main lymphoma part of the meeting, we will also exclude overt large B cell lymphoma including Richter-type transformation, all EBV-positive and/or immunodeficiency associated proliferations or lymphomas, plasma cell neoplasms with the notable exceptions of lymphoplasmacytic lymphoma and MZL plasmacytic.